PE20151062A1 - PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACION SIN SENTIDO - Google Patents

PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACION SIN SENTIDO

Info

Publication number
PE20151062A1
PE20151062A1 PE2015000911A PE2015000911A PE20151062A1 PE 20151062 A1 PE20151062 A1 PE 20151062A1 PE 2015000911 A PE2015000911 A PE 2015000911A PE 2015000911 A PE2015000911 A PE 2015000911A PE 20151062 A1 PE20151062 A1 PE 20151062A1
Authority
PE
Peru
Prior art keywords
quinoline
pyrimid
sense
dionas
diona
Prior art date
Application number
PE2015000911A
Other languages
English (en)
Spanish (es)
Inventor
Edgar Jacoby
Juergen Reinhardt
Niko Schmiedeberg
Carsten Spanka
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151062(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20151062A1 publication Critical patent/PE20151062A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Inorganic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2015000911A 2012-12-13 2013-12-12 PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACION SIN SENTIDO PE20151062A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261736748P 2012-12-13 2012-12-13

Publications (1)

Publication Number Publication Date
PE20151062A1 true PE20151062A1 (es) 2015-08-05

Family

ID=50030361

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000911A PE20151062A1 (es) 2012-12-13 2013-12-12 PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACION SIN SENTIDO

Country Status (24)

Country Link
US (2) US9649314B2 (enExample)
EP (1) EP2931282B1 (enExample)
JP (1) JP6076498B2 (enExample)
KR (1) KR101760586B1 (enExample)
CN (2) CN107569487A (enExample)
AP (1) AP2015008441A0 (enExample)
AU (1) AU2013358591B2 (enExample)
BR (1) BR112015013535A2 (enExample)
CA (1) CA2890692A1 (enExample)
CL (1) CL2015001610A1 (enExample)
CR (1) CR20150314A (enExample)
CU (1) CU20150061A7 (enExample)
EA (1) EA028673B1 (enExample)
ES (1) ES2709034T3 (enExample)
HK (1) HK1209637A1 (enExample)
IL (1) IL239244A0 (enExample)
IN (1) IN2015DN03998A (enExample)
MA (1) MA38157A1 (enExample)
MX (1) MX363437B (enExample)
PE (1) PE20151062A1 (enExample)
PH (1) PH12015501216A1 (enExample)
SG (1) SG11201503684WA (enExample)
TN (1) TN2015000262A1 (enExample)
WO (1) WO2014091446A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX363437B (es) 2012-12-13 2019-03-22 Novartis Ag Pirimido-4,5-b]-quinolina-4,5 (3h,10h)-dionas como supresoras de mutacion sin sentido.
WO2015186062A1 (en) * 2014-06-03 2015-12-10 Novartis Ag PYRIMIDO[4,5-b]QUINOLINE-4,5(3H,10H)-DIONE DERIVATIVES
EP3152207B1 (en) 2014-06-03 2019-05-08 Novartis AG Pyridopyrimidinedione derivatives as suppressors of non-sens mutations
CA2950724A1 (en) * 2014-06-03 2015-12-10 Novartis Ag Naphthyridinedione derivatives
US10960018B2 (en) * 2016-04-15 2021-03-30 The Uab Research Foundation Methods and compounds for stimulating read-through of premature termination codons
WO2019173437A1 (en) * 2018-03-06 2019-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Positive allosteric modulators of dopamine 1 receptor and method of use thereof
WO2019225625A1 (ja) * 2018-05-23 2019-11-28 京都薬品工業株式会社 リードスルー誘導剤およびその医薬用途
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
WO2024194607A1 (en) 2023-03-17 2024-09-26 Tay Therapeutics Limited Pyrimido[4,5-b][1,5]naphthyridine-4,5(3h,10h)-dione derivatives for the treatment of diseases associated with ptc mutations, such as e.g. cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884170B2 (ja) * 1989-08-24 1999-04-19 株式会社フジモト・ブラザーズ ５−デアザフラビン系化合物を有効成分とする制癌剤
WO1996028444A1 (en) 1995-03-15 1996-09-19 Pfizer Inc. 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004006906A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Methods for the treatment of neoplasms
EP4101846B1 (en) 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
HUE031643T2 (en) 2006-04-03 2017-07-28 Technion Res & Dev Foundation New aminoglycosides and their applications in the treatment of genetic disorders
US20080090845A1 (en) 2006-08-23 2008-04-17 Neurogen Corporation Haloalkyl-substituted pyrimidinone derivatives
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2422817A1 (en) 2010-07-29 2012-02-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Flavin-nucleic acid ligand conjugates
JP5877200B2 (ja) 2010-08-05 2016-03-02 ユニヴェルシテ ドゥ ドロワ エ サンテ ドゥ リール ナンセンス突然変異による疾患の治療に有用な化合物及びその化合物を含む医薬組成物
MX363437B (es) 2012-12-13 2019-03-22 Novartis Ag Pirimido-4,5-b]-quinolina-4,5 (3h,10h)-dionas como supresoras de mutacion sin sentido.

Also Published As

Publication number Publication date
KR101760586B1 (ko) 2017-07-21
IN2015DN03998A (enExample) 2015-10-02
EA201591105A1 (ru) 2015-10-30
HK1209637A1 (en) 2016-04-08
EA028673B1 (ru) 2017-12-29
EP2931282B1 (en) 2018-10-31
IL239244A0 (en) 2015-07-30
KR20150092306A (ko) 2015-08-12
JP2016503003A (ja) 2016-02-01
AP2015008441A0 (en) 2015-05-31
ES2709034T3 (es) 2019-04-12
EP2931282A1 (en) 2015-10-21
TN2015000262A1 (en) 2016-10-03
PH12015501216A1 (en) 2015-08-17
MX363437B (es) 2019-03-22
MA38157A1 (fr) 2016-12-30
US20170266189A1 (en) 2017-09-21
CN107569487A (zh) 2018-01-12
CL2015001610A1 (es) 2015-08-07
WO2014091446A1 (en) 2014-06-19
US9649314B2 (en) 2017-05-16
SG11201503684WA (en) 2015-06-29
CA2890692A1 (en) 2014-06-19
US20150335646A1 (en) 2015-11-26
CU20150061A7 (es) 2015-12-23
MX2015007562A (es) 2015-10-14
CN104837490A (zh) 2015-08-12
CR20150314A (es) 2015-08-10
AU2013358591A1 (en) 2015-05-28
BR112015013535A2 (pt) 2017-07-11
CN104837490B (zh) 2017-10-03
JP6076498B2 (ja) 2017-02-08
AU2013358591B2 (en) 2016-08-25

Similar Documents

Publication Publication Date Title
MX2015015412A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
MX2018014758A (es) Piridinas sustituidas con heteroarilo y metodos de uso.
MY193728A (en) Muscarinic receptor agonists
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
UA122498C2 (uk) Біциклічні похідні, спосіб їх отримання та фармацевтичні композиції, що їх містять
CL2012003427A1 (es) Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras.
CL2015000829A1 (es) Inhibidores de histona desmetilasas
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
PE20151558A1 (es) Inhibidores tripeptidicos de la epoxicetona proteasa
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2017012346A (es) Cuerpo mixto novedoso de compuesto de hierro y oxido de grafeno.
SG10201805628TA (en) Deuterated heterocyclic compounds and their use as imaging agents
SA518390788B1 (ar) مركب يستهدف إنترلوكين- 23 أ وعامل تنشيط الخلايا البائية واستخداماته
PH12013502434A1 (en) Substituted pyridopyrazines as novel syk inhibitors
PE20150709A1 (es) Benzamidas
CL2015002897A1 (es) Inhibidores de bace1
PH12015502118A1 (en) Pyridin-4-yl derivatives
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
CL2017001100A1 (es) Nuevas triazolo[4,5-d]pirimidinas
PE20151055A1 (es) Compuestos triciclicos para inhibir el canal cftr

Legal Events

Date Code Title Description
FD Application declared void or lapsed